Glucose-insulin-potassium infusion in patients with acute myocardial infarction without signs of heart failure: the Glucose-Insulin-Potassium Study (GIPS)-II.

摘要

Metabolic support through glucose-insulin-potassium (GIK), in adjunct to reperfusion therapy, might improve outcome in patients with ST-segment elevation myocardial infarction (STEMI). The Glucose-Insulin-Potassium Study (GIPS)-I showed clinical benefit of GIK in STEMI patients without signs of heart failure. To verify these findings we performed a second study investigating GIK in patients without signs of heart failure treated with reperfusion therapy.It concerns a randomized, open label study; STEMI patients without signs of heart failure on admission were randomized to traditional care or additional GIK infusion. Glucose-potassium (20% glucose with 80 mmol potassium/l) was infused at 2 ml/kg body weight per hour for 12 h through a peripheral line. Short-acting insulin was started according to admission glucose and adjusted on the basis of hourly measured glucose.